Global Partnerships

Humanitarian Programs of the Pharmaceutical Industry in Developing Nations
Pharmaceutical companies contribute financial aid, medicine and expertise to many of the world’s leading humanitarian, academic, governmental, multilateral and community-based organizations to relieve suffering and improve public health in the developing world. A partial list of our partners includes:

<table>
<thead>
<tr>
<th>International HIV/AIDS Alliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Labor Organization</td>
</tr>
<tr>
<td>International Medical Services for Health</td>
</tr>
<tr>
<td>International Planned Parenthood Federation</td>
</tr>
<tr>
<td>International Rescue Committee</td>
</tr>
<tr>
<td>Johns Hopkins School of Public Health</td>
</tr>
<tr>
<td>Kenya Ministry of Health</td>
</tr>
<tr>
<td>Lions Club International</td>
</tr>
<tr>
<td>Makarere University</td>
</tr>
<tr>
<td>Mali Ministry of Health</td>
</tr>
<tr>
<td>MAP International</td>
</tr>
<tr>
<td>Medical Education for South African Blacks</td>
</tr>
<tr>
<td>Millennium Vaccine Initiative</td>
</tr>
<tr>
<td>Morocco Ministry of Health</td>
</tr>
<tr>
<td>National Children’s Cancer Society</td>
</tr>
<tr>
<td>Nelson Mandela Foundation</td>
</tr>
<tr>
<td>Operation Smile</td>
</tr>
<tr>
<td>Overseas Development Institute</td>
</tr>
<tr>
<td>PAHO Diabetes Project (Chile)</td>
</tr>
<tr>
<td>Pan American Health Organization</td>
</tr>
<tr>
<td>Partnership for Child Development</td>
</tr>
<tr>
<td>Partners in Health</td>
</tr>
<tr>
<td>PharmAccess International</td>
</tr>
<tr>
<td>The Population Council</td>
</tr>
<tr>
<td>Population Services International</td>
</tr>
<tr>
<td>Project HOPE</td>
</tr>
<tr>
<td>Purdue University</td>
</tr>
<tr>
<td>Romanian National AIDS Committee</td>
</tr>
<tr>
<td>Rotary International</td>
</tr>
<tr>
<td>Rwandan National Center for AIDS</td>
</tr>
<tr>
<td>Save the Children</td>
</tr>
<tr>
<td>Sightsavers International</td>
</tr>
<tr>
<td>South African Medical Research Council</td>
</tr>
<tr>
<td>Taiwan Department of Health</td>
</tr>
<tr>
<td>Tanzania Ministry of Health</td>
</tr>
<tr>
<td>Task Force for Child Survival &amp; Development</td>
</tr>
<tr>
<td>Thailand Ministry of Health</td>
</tr>
<tr>
<td>Transparency International</td>
</tr>
<tr>
<td>Uganda Business Coalition on HIV/AIDS</td>
</tr>
<tr>
<td>Uganda Ministry of Health</td>
</tr>
<tr>
<td>Ugandan AIDS Commission</td>
</tr>
<tr>
<td>UNAIDS</td>
</tr>
<tr>
<td>UNFPA (United Nations Population Fund)</td>
</tr>
<tr>
<td>UN High Commissioner for Refugees</td>
</tr>
<tr>
<td>UNICEF (United Nations Children’s Fund)</td>
</tr>
<tr>
<td>United Nations</td>
</tr>
<tr>
<td>USAID</td>
</tr>
<tr>
<td>U.S. Fund for UNICEF</td>
</tr>
<tr>
<td>University of Cape Town</td>
</tr>
<tr>
<td>University of KwaZulu-Natal</td>
</tr>
<tr>
<td>University of New South Wales (Australia)</td>
</tr>
<tr>
<td>Vietnamese Women’s Union</td>
</tr>
<tr>
<td>Vietnam Ministry of Health</td>
</tr>
<tr>
<td>VSO (Voluntary Services Overseas)</td>
</tr>
<tr>
<td>World Bank</td>
</tr>
<tr>
<td>World Federation of Mental Health</td>
</tr>
<tr>
<td>World Health Organization</td>
</tr>
<tr>
<td>World Psychiatric Association</td>
</tr>
<tr>
<td>World YWCA</td>
</tr>
<tr>
<td>WHO Global Alliance to Eliminate Leprosy</td>
</tr>
<tr>
<td>World Vision Foundation</td>
</tr>
<tr>
<td>Government of Zambia</td>
</tr>
</tbody>
</table>

Aaron Diamond AIDS Research Centre  
African Council of AIDS Service Organizations  
African Medical & Research Foundation  
Africare  
AfriCASO  
AIDS Empowerment and Treatment International  
Agua Buena Human Rights Association  
American Red Cross  
American Schools Abroad  
AmeriCares  
Armenian Eyecare Project  
Association RIVÉ  
Axios International  
Baylor Children’s Hospital  
Bill & Melinda Gates Foundation  
Republic of Botswana  
Brigham and Women’s Hospital  
British Red Cross  
Government of Cambodia  
CARE  
Carter Center/Global 2000  
Catholic Medical Mission Board  
Catholic Relief Services  
Centers for Disease Control Foundation  
Center for Diabetes and Endocrinology  
Centre Hospitalier Universitaire du Rwanda  
Centre National d’Appui à la Lutte contre la Maladie (Mali)/Center for Vaccine  
Cithope International  
China Academy of Medical Science  
China Liver Foundation  
Chris Hani Baragwanath Hospital (Soweto)  
Colombia Ministry of Health  
Community Health and Information Network  
CORE (Congress of Racial Equality)  
Declaration of the Americas  
Diabetes Project  
Doctors Without Borders (Medecins Sans Frontiers)  
Edna McConnell Clark Foundation  
Egyptian Ministry of Health  
Elizabeth Glaser Pediatric AIDS Foundation  
Ethics Institute of South Africa  
European Coalition of Positive People  
European Union  
FUNDALIU  
GERMAN PHARMA Health Fund  
Ghana Diabetes Care  
Global Alliance for Vaccines & Immunizations  
Global Business Coalition on HIV/AIDS  
Global Fund to Fight AIDS, TB and Malaria  
Harvard AIDS Institute  
Helen Keller International  
HOPE  
HUMANA People to People  
Hungarian Diabetes Association  
Indiana University School of Medicine/  
Moi University Faculty of Health Sciences (Kenya)  
Indiana University/Argentina Diabetes Society  
Indonesia University’s Public Health Faculty  
Interchurch Medical Assistance  
International AIDS and Economics Network  
International AIDS Vaccine Initiative  
International Center for Research on Women  
International Council of AIDS Service Organizations  
International Council of Nurses  
International Diabetes Foundation  
International Long-Term Care Policy Network  
International Medical Services for Health  
International Planned Parenthood Federation  
International Rescue Committee  
Johns Hopkins School of Public Health  
Kentucky Ministry of Health  
Lions Club International  
Makarere University  
Mali Ministry of Health  
MAP International  
Medical Education for South African Blacks  
Millennium Vaccine Initiative  
Morocco Ministry of Health  
National Children’s Cancer Society  
Nelson Mandela Foundation  
Operation Smile  
Overseas Development Institute  
PAHO Diabetes Project (Chile)  
Pan American Health Organization  
Partnership for Child Development  
Partners in Health  
PharmAccess International  
The Population Council  
Population Services International  
Project HOPE  
Purdue University  
Romanian National AIDS Committee  
Rotary International  
Rwanda Center for Child Development  
Save the Children  
Sightsavers International  
South African Medical Research Council  
Taiwan Department of Health  
Tanzania Ministry of Health  
Task Force for Child Survival & Development  
Thailand Ministry of Health  
Transparency International  
Uganda Business Coalition on HIV/AIDS  
Uganda Ministry of Health  
Ugandan AIDS Commission  
UNAIDS  
UNFPA (United Nations Population Fund)  
UN High Commissioner for Refugees  
UNICEF (United Nations Children’s Fund)  
United Nations  
USAID  
U.S. Fund for UNICEF  
University of Cape Town  
University of KwaZulu-Natal  
University of New South Wales (Australia)  
Vietnamese Women’s Union  
Vietnam Ministry of Health  
VSO (Voluntary Services Overseas)  
World Bank  
World Federation of Mental Health  
World Health Organization  
World Psychiatric Association  
World YWCA  
WHO Global Alliance to Eliminate Leprosy  
World Vision Foundation  
Government of Zambia
With few exceptions, research-based pharmaceutical companies have always been well represented on the various lists of America’s best employers, most respected companies, best workplaces for women and minorities and best corporate citizens. Not as well known is the important role the industry plays in the global effort to fight disease and improve public health in the developing world. In both absolute and relative terms the industry’s global humanitarian programs are substantial, sustained and effective.

In a span of three years the industry’s global healthcare spending increased 148 percent, from $564 million to $1.4 billion.1 Another study puts the industry’s contribution at $2.1 billion. Our contribution to global health represents more than a third of the United States’ total healthcare assistance to the developing world.

In addition, our partnerships with leading academic, governmental, multilateral, non-governmental and community-based organizations exceed or rival in total size the annual budgets of the World Health Organization and the World Bank’s health programs, among others.

Perhaps most important is the long-term commitment our companies have made to these partnerships. More than 93 percent of the industry’s global activities involve a sustained commitment. Many date back more than a decade and as many involve formal commitments far into the future. An important reason for this is that building these partnerships is hard work, requiring great amounts of time, resources and, in some cases, courage on the part of our employees.

The global partnerships detailed in this report have benefited tens of millions of people living in more than 100 developing countries around the world. Nevertheless, these partnerships are but representative of all of the industry’s many humanitarian programs in the developing world.

---

**HOW THE INDUSTRY COMPARES**

<table>
<thead>
<tr>
<th></th>
<th>Global Health Spending in 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Industry</td>
<td>$1.4 Billion - $2.1 Billion*</td>
</tr>
<tr>
<td>European Union</td>
<td>$850 Million</td>
</tr>
<tr>
<td>World Bank</td>
<td>$1.03 Billion</td>
</tr>
<tr>
<td>UNICEF</td>
<td>$1.3 Billion</td>
</tr>
<tr>
<td>WHO</td>
<td>$1.37 Billion</td>
</tr>
<tr>
<td>USAID</td>
<td>$1.37 Billion</td>
</tr>
</tbody>
</table>

*Partner for Quality Medical Donations; Center for Science in Public Policy, Hudson Institute

1 Partnership for Quality Medical Donations’ estimate of $1.4 billion in industry spending does not include the value of drugs and in-kind donations made by as many as 24 non-PQMD pharmaceutical companies to non-PQMD non-governmental organizations. Nor does it account for donated medical care and other services by company employees. PQMD corporate members include Abbott Laboratories, BD, Boehringer Ingelheim, Bristol-Myers Squibb Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., and Wyeth Pharmaceuticals. Humanitarian members include AmeriCares, Catholic Medical Mission Board, Direct Relief International, Heart to Heart International, Interchurch Medical Assistance, Inc., International Aid, MAP International, Mercy Ships, Northwest Medical Teams, Project HOPE, U.S. Fund for UNICEF and World Vision.
The Global Targets

The humanitarian programs of pharmaceutical companies often focus on combating specific diseases or health conditions endemic to developing countries. Examples include:

**HIV/AIDS**

- 90,000 AIDS orphans and vulnerable children helped by donated testing, counseling, educational programs, infrastructure improvements and community development (Abbott)
- Rapid HIV tests and antiretroviral (ARV) medicines provided at no profit in 68 developing countries (Abbott)
- Free tests and medicines to pregnant women (Abbott and Boehringer Ingelheim)
- With the government of Tanzania and local organizations, the renovation and modernization of Muhimbili National Hospital and 21 regional hospitals and staff training on HIV care (Abbott)
- ARV medicine that prevents mother-to-child transmission of HIV-1 donated to 100 programs in 50 countries, including China, Russia and Peru (Boehringer Ingelheim)
- Working with the Zambian Nurses Association to provide free ARV drugs to pregnant nurses (Boehringer Ingelheim)
- Granted a license to a South African firm to manufacture and market a generic version of VIRAMUNE® in Africa (Boehringer Ingelheim)
- Diagnostic and research facility constructed in Singureni, Romania, to assist in testing orphans, street children and young adults for HIV (Bayer)
- Grants totaling almost $100 million to more than 160 community and medical research organizations in nine African nations (Bristol-Myers Squibb)
- Funding community-based clinics and outreach programs for children with HIV in six African nations (Bristol-Myers Squibb)
- With the Thai Red Cross, HIV prevention program for young people (Bristol-Myers Squibb)
- Sponsor programs in China to prevent the spread of HIV among young people and drug users (GlaxoSmithKline)
- Supporting 32 programs in 13 countries in Francophone Africa to improve access to healthcare for HIV-positive people (GlaxoSmithKline)
- 27 clinical trials to assess the use of ARV drugs in resource-poor settings (GlaxoSmithKline)
- Pledge not to file patents on new ARV therapies or take action against generic versions in the Least Developed Countries and sub-Saharan Africa (Hoffman-La Roche)
- Partnering with humanitarian organization to provide counseling, testing and ARV medicines to prevent transmission of HIV from mothers to babies in India (Johnson & Johnson)
- Supporting “Rainbow Camps” for HIV-affected children in Thailand (Johnson & Johnson)
- Providing medicines and other support for home-based care of HIV patients in Soweto and Uganda (Johnson & Johnson)
- Supporting foundation that provides homes and other support for children and adults living with AIDS in Colombia (Johnson & Johnson)
- Supporting a program to mobilize communities against the spread of HIV in Soweto (Johnson & Johnson)
- Mobile counseling services provided to HIV-infected youth supported in Cambodia (Johnson & Johnson)
- Peer training program for HIV-infected youth supported in Peru (Johnson & Johnson)
- Donated 130,000 treatments of a medicine to combat an opportunistic fungal infection in AIDS patients (Johnson & Johnson)
- $50 million to enhance Botswana’s national response to HIV/AIDS in the areas of prevention, treatment, care and support (Merck)
- ARV medicines for more than 15,000 patients donated to Botswana’s national ARV treatment program, currently the largest in Africa (Merck)
- $5 million for care teams to design practical improvements in HIV care in Brazil, Senegal, South Africa and Thailand (Merck)
Partnership with shipping company to deliver, at cost, HIV medicines by air express to treatment centers throughout sub-Saharan Africa (Merck)

Sponsored training for 12 Rwandan physicians who now serve as their country’s referral physicians for ARV therapy. 136 newly trained healthcare professionals (secondary level of care) are in turn training healthcare workers from primary healthcare centers nationwide (Merck)

Since 1997, support for clinical HIV training through local workshops, scientific conferences and clinical preceptorships for more than 2,200 African physicians from 24 countries (Merck)

Since 1997, have worked with the Government of Romania to increase access to treatment for children and adults living with HIV/AIDS by establishing a network of regional treatment centers (Merck)

More than 4 million free doses of antifungal medicine to treat 87,000 patients at 915 sites in 23 countries in Africa, Asia, Carribean and Latin America (Pfizer)

18,000 healthcare providers trained in HIV treatment and care (Pfizer)

Providing company physicians, nurses and other specialists to non-governmental organizations (NGOs) working to fight HIV/AIDS (Pfizer)

Supported the construction of a recently opened medical facility to provide state-of-the-art HIV/AIDS care in Uganda (Pfizer)

Grants to support innovative HIV/AIDS health promotion programs in developing countries (Pfizer)

With the Cambodian government and the University of New South Wales in Australia, program created to widen access to sustainable healthcare, including ARV medicines (Hoffman-LaRoche)

Malaria

Running a Tropical Disease Center in Brazil to help control malaria (Aventis)

Funding project to identify new ways to use existing therapies to reduce the toll of malaria in the Ivory Coast (Aventis)

Working with the WHO to develop a new malaria drug to be marketed in developing countries at affordable prices (Bayer)

Malaria prevention programs supported in Malawi, Mali, Turkey and Zambia (Bayer)

In October 2004, results from the largest pediatric safety and efficacy clinical trial of malaria vaccine in Africa published in *The Lancet* (GlaxoSmithKline)

With the WHO developing a fixed-dose combination therapy drug for malaria (GlaxoSmithKline)

$1.5 million in support of malaria education programs for 2 million people in seven African countries (GlaxoSmithKline)

Anti-malarial medicines offered at no-profit prices in 63 of the world’s poorest countries (GlaxoSmithKline)

Providing unlimited quantities of malaria drug at cost for public sector use in Africa, Asia and Latin America (Novartis)

Through “Impact Malaria” program, working with governments and other organizations to provide education, prevention and treatment information to healthcare providers and patients and to provide treatment in developing countries at affordable prices (Sanofi-Synthelabo)

Tuberculosis

Donated £100,000 to fight tuberculosis (TB) in Kyrgyzstan and Turkmenistan through education, testing, treatment and care (AstraZeneca)

$30 million grant for TB research in India (AstraZeneca)

Working with the Nelson Mandela Foundation to increase testing, care and treatment of TB in South Africa (Aventis)

Supporting research and training program on multi-drug resistant TB in Siberia (Lilly)

$70 million partnership with the WHO and others involving supply of two antibiotic drugs at discounted price to fight multi-drug resistant TB (Lilly)

A newly completed expansion of manufacturing capacity which will double the production of the antibiotic capreomycin (Lilly)

Technology transfer agreements with companies in India and South Africa to manufacture anti-TB drug (Lilly)

Donating 100,000 doses of TB medicine a year for five years to Tanzania (Novartis)

Donation of the WHO-recommended rifampicin-based fixed-dose combination for 500,000 patients (Novartis)

Funds $122 million Institute for Tropical Diseases in Singapore which focuses on developing therapies for TB and dengue fever (Novartis)

Working with UNICEF to provide TB vaccinations to more than 8 million people in Senegal (Proctor & Gamble)
The Global Targets

Hepatitis B
- Educating healthcare workers, physicians and villages on hepatitis prevention, care and treatment (Bristol-Myers Squibb)
- 1 million doses of hepatitis B vaccine donated every year for five years in support of the Global Alliance for Vaccines and Immunizations and the Millennium Vaccine Initiative (Merck)
- Provided hepatitis B vaccine in Vietnam and Colombia (Sanofi-Synthelabo)

Polio
- Donating more than 30 million doses of polio vaccine in 16 African countries—a total of 130 million doses donated in Africa since 1997. In 2000, 550 million children were immunized, 152 million of them in India (Aventis)

Lymphatic Filariasis
- Approximately 20 million people in eight African countries and Yemen received Mectizan last year alone for the treatment of LF (Merck)
- 94 million albendazole tablets donated to the WHO’s Global Program to Eliminate Lymphatic Filariasis, a total of 250 million tablets in almost 40 countries (GlaxoSmithKline)

Onchocerciasis (River Blindness)
- Donating Mectizan to all who need it, for as long as needed, to treat river blindness in sub-Saharan Africa, Latin America and Yemen. Treatment programs currently exist in 34 endemic countries, providing 40 million doses of Mectizan for river blindness each year (Merck)
- $1 million grant to The Carter Center to further support onchocerciasis elimination efforts in Latin America (Merck)

Blinding Trachoma
- Through the International Trachoma Initiative, providing a key antibiotic to countries implementing public health programs to combat trachoma. 10 million treatments, valued at $225 million, donated to date (Pfizer)
- Provided 21 research grants for the study of trachoma (Pfizer)
- Expansion of product donation and health education grants to 10 new country programs, involving donation of 135 million treatments (Pfizer)

“Trachoma is a disease that causes immense and unnecessary pain and suffering. It’s very gratifying to be partnered with Pfizer in this global commitment to the alleviation of suffering—to bringing hope to people who quite often in the past have never known the meaning of the word.”

Jimmy Carter
Former U.S. President
Nobel Laureate

Leprosy
- Providing free medicines, valued at $4 million in 2003, to the WHO initiative to eliminate leprosy (Novartis)
- 2.5 million patients cured of leprosy by donated medicines (Novartis)

Sleeping Sickness
- Working with the WHO, committed $25 million to accelerate disease control and prevention and R&D and donated three medicines for sleeping sickness (Aventis)
- In partnership with the WHO, donating a drug to combat sleeping sickness in developing countries (Bayer)
- Research and development on the off-label use of a drug for Chagas disease for sleeping sickness (Bayer)

Other Diseases/ Health Conditions
- Free medicines to treat African children with Burkitt’s lymphoma (Aventis)
- Funds a Tropical Disease Center in Brazil that works to control and treat leishmaniasis (Aventis)
- $70,000 worth of genetically engineered human insulin donated to the Kyrgyz Republic for treatment of diabetes (Aventis)
- 25,000 doses of meningitis vaccine donated to the WHO for Burkina Faso (Aventis)
- Partnering with local government in a dengue fever prevention program aimed at school children (Bayer)
- Working with health authorities in the Dominican Republic and Guatemala to reduce the incidence of dengue fever through mosquito control (Bayer)
- Supports education programs to prevent dengue fever in Ecuador and Paraguay (Bayer)
- With the Australian government raise awareness of diabetes among the aboriginal population through testing and monitoring (Bayer)
- Donated supplies to El Salvador to combat dengue fever (Bayer)
- Supports a camp for children with hemophilia in Taiwan (Bayer)
- Psychological counseling for 120,000 cancer patients in Hungary (Bristol-Myers Squibb)
Working with AmeriCares to address high rates of respiratory infections in cities in Mexico (Bristol-Myers Squibb)

Enough donated medical supplies such as medicine, forceps and gauze to treat guinea worm in more than 3,000 villages (Johnson & Johnson)

Working with Project Hope on diabetes management programs in China and Egypt (Lilly)

$180,000 commitment to the International Diabetes Foundation Child Sponsorship Program, which helps diabetic children and adolescents in developing countries with insulin, equipment and knowledge needed to successfully manage diabetes (Lilly)

$120,000 worth of Xigris donated to China for the treatment of SARS patients who develop severe sepsis (Lilly)

Funding a diabetes clinic in an impoverished area of Johannesburg, South Africa, for screening, diagnosis, treatment management and education (Lilly)

Partnering with Project Hope to provide enzyme therapy in Belarus, China, Cuba, Ecuador, Egypt, Haiti, India, Jamaica, Kenya, Pakistan, Sri Lanka, Tanzania, Ukraine, Vietnam and Yugoslavia (Genzyme)

Working with health authorities in Peru and Zambia to reduce diarrhearelated disease in schoolchildren (GlaxoSmithKline)

Provided vitamin A supplements to 250,000 children in India to prevent blindness (Johnson & Johnson)

$1 million for leukemia awareness program, blood sample testing and data bank in China (Johnson & Johnson)

1 million doses of MMR II (mumps, measles, rubella vaccine) donated to help eradicate measles from the Western Hemisphere (Merck)

Working to improve water purity in Egypt and reduce the incidence of waterborne diseases such as shistosomiasis and fasciola (Proctor & Gamble)

Other Capacity-Building Activities

Mobile clinic on rails that brings basic medical services to people in remote parts of South Africa (3M, Hoffmann-LaRoche)

Support for the Armenian Eyecare Project (Allergan)

Mobile Eye Hospital in China (Allergan)

Textbooks donated to medical schools in 37 countries (AstraZeneca)

Ambulance donated to a trauma center in India (AstraZeneca)

Three mobile clinics donated to a poverty-stricken region of South Africa (AstraZeneca)

12-year-old capacity-building program that has helped 39 international programs in partnership with 28 community-based organizations in 34 countries (GlaxoSmithKline)

Support for a hospital management program in Singapore (Johnson & Johnson)

$5 million grant to the WHO to improve mental health in developing countries (Lilly)

Training in vaccine management and immunization services for immunization program managers in Africa (Merck)

Partnership with the International Council of Nurses and publisher to bring 80 mobile medical libraries of up-to-date educational and reference materials to rural nurses in Swaziland, Kenya, Zimbabwe, Ethiopia, Somalia, Botswana, Tanzania, Zambia and Ghana (Merck)

Donating copies of medical manuals to doctors and other health care personnel in South Africa and Latin America (Merck)

Through a Global Health Fellows Program lends company professionals to NGOs working in developing countries (Pfizer)

Support for “fun center” for children in hospitals in Brazil (Sanofi-Synthelabo)

Working with Syrian government to improve services at 10 major health centers, including refurbishing buildings and donating equipment (Proctor & Gamble)
3M Pharmaceuticals — In 2003, 3M donated $1.2 million in healthcare and other products to conflict areas and developing countries through Project HOPE and Map International.

Working in conjunction with Project HOPE and the Shanghai Second Medical University, 3M helped develop a medical center to address children’s healthcare needs.

In partnership with Hoffman La Roche, 3M sponsors Phelophepa, a clinic on rails that has been bringing basic medical services to people in remote parts of South Africa since 1994. The train is fully equipped to provide general medical services and dental, eye and psychiatric care.

3M donated air-powered instruments for orthopedic surgery to the Mseleni Hip Clinic in KwaZulu-Natal, South Africa. The donated instruments help increase the number of surgical procedures performed on needy South African patients.

Abbott Laboratories — Abbott and the Abbott Laboratories Fund invested over $20 million in global HIV programs in 2002 and expect to invest a total of $100 million by 2007. With respect to global healthcare initiatives overall, Abbott contributed more than $225 million in cash grants and product donations in 2003.

Step Forward … for the World’s Children

Step Forward assists orphans of AIDS and vulnerable children worldwide by providing voluntary HIV testing and counseling, improving local health infrastructure and services, strengthening education at the primary and secondary levels, meeting basic community needs such as clean water and promoting local economic development. Step Forward collaborates with national, regional and local governments, international organizations and NGOs in India, Romania, Tanzania, and Burkina Faso. In 2003, 140,000 orphans, vulnerable children and families were served.

Abbott Access

Beginning in 2001, Abbott Access has provided rapid HIV tests and ARVs at no profit in 68 countries, including all of Africa and 49 Least Developing Countries (LDCs). In 2003, more than 6.6 million tests were shipped to 55 countries.

Abbott Determine® HIV Prevention Program

In June 2002, Abbott committed to donating up to 20 million of its Determine® HIV rapid tests to programs addressing mother-to-child transmission of HIV in 68 developing countries, including all of Africa. Since then, approximately 670,000 tests have been shipped at no profit for Abbott.

In September 2003, Abbott Laboratories announced a cooperative arrangement with Boehringer Ingelheim to provide HIV tests and ARV treatment to pregnant women in the developing world. Through the agreement, organizations that support qualified prevention of mother-to-child transmission are eligible to receive Abbott's rapid HIV test, as well as BI’s ARV VIRAMUNE® for those mothers who test positive for HIV.

Tanzania Care

Abbott works with the Government of Tanzania, local organizations and contractors in a program to renovate and modernize Muhimbili National Hospital, extend voluntary HIV testing and counseling to the country’s 21 regional hospitals, and train staff on HIV care and treatment. Muhimbili National Hospital will become a “Center of Excellence” by regaining its role as the country’s primary research, referral and teaching facility.

“Creative new public/private partnerships combine finances, technical expertise, prestige, political influence and the potential to transfer skills to governmental and non-governmental bodies. Public-private partnerships will provide a base for addressing the next generation of issues; the critical, enduring challenges of how to build a greatly enlarged pool of skilled personnel, to extend services effectively to local communities, to build up the non-governmental sector, and to empower women and persons living with the HIV virus.”

Randall Tobias
U.S. Global AIDS Coordinator
December 2003
In December 2003, Abbott worked in partnership with AmeriCares and the Afzalipour Medical Center in Kerman, Iran, to deliver antibiotics, anesthetics and other medical supplies to the victims of the Bam earthquake. Abbott has also supported disaster relief efforts for victims of the Mozambique and Cambodia floods, the famine in Ethiopia, the war in Iraq and the Dengue fever outbreak in El Salvador.

Allergan, Inc. — Allergan grants have provided financial support for the global activities of the following organizations:

The Armenian Eyecare Project
Physicians travel to poverty-stricken Armenia to help restore sight to Armenians in need.

The Blindness Foundation
Training, education, equipment and instruments, as well as medical supplies and materials, to serve the needs of the cataract blind in central Burma.

Direct Relief International
Help people in the developing world achieve healthier, more productive lives by strengthening local health facilities and programs.

Heart-to-Heart International
Supply a Mobile Eye Hospital in China with appropriate equipment and medicines as well as surgical training for physicians.

Medical Services International, Inc.
Affordable eye care to areas in rural China including surgery and post-operative care, training of local eye specialists and treatment of non-surgical conditions.

Pan American Ophthalmic Foundation
Reduce health disparities among and within the countries of the Western Hemisphere.

Pan American Ophthalmic Foundation
Development of a training video for hospital/medical personnel to effectively assist visually challenged patients.

Surgical Eye Expeditions International
Recruit, coordinate and deploy volunteer ophthalmologists, nurses and technicians to perform free, sight-developing surgery.

World Eye Mission
Ophthalmic care to under served communities worldwide.

AstraZeneca — In partnership with UK-based BookPower, AstraZeneca will provide medical and nursing textbooks, valued at £60,000, for use in medical schools in 37 English-speaking countries in Africa, the Indian subcontinent and the Caribbean.

AstraZeneca Discovery Bangalore
In June 2003, AstraZeneca underscored its commitment to TB research with an additional $30 million, 5-year grant to the Indian research facility. TB diagnostic tests and therapeutic medicines developed in the Bangalore laboratories will be made available to developing countries at low cost in partnership with governments, international organizations and NGOs.

Working in conjunction with the Red Cross, government health ministers, local officials and schools, AstraZeneca donated £300,000 over three years to fight TB in Kyrgyzstan and Turkmenistan. The program broadly focuses on education, testing, treatment and care of those living with TB and represents the company’s ongoing commitment to address TB in developing countries.

National Schools Program, South Africa
In partnership with the National Asthma Education Program, AstraZeneca is working to improve asthma awareness and education in South African public schools.
GLOBAL HEALTH SUCCESSES

* Since 1988, the Global Polio Eradication Initiative, with support from Aventis Pasteur, has slashed polio cases by more than 99 percent, from 1,000 cases per day to 1,000 cases per year.

* In October 2004, the largest ever unified health drive—a polio immunization campaign in 23 countries to protect 60 million children—began.

(International Herald Tribune, October 28, 2004)

The African Institute of Biomedical Science and Technology

Since the institute was founded in 2001, AstraZeneca, the WHO and UNESCO have been working together to promote the science and technology of drug discovery, development and use in Africa through courses, workshops, symposia and research.

Iressa Global Access Program

During 2002 and 2003, more than 42,000 patients in 70 countries received Iressa, AstraZeneca’s lung cancer treatment.

AstraZeneca Argentina works in conjunction with Fundación Margarita Barrientos and Fundación María Virgen Madre to provide housing, medical, educational and mental assistance to underprivileged and abandoned children.

In 1995, AstraZeneca South Africa donated three self-contained mobile clinics to help promote primary healthcare in a poverty-stricken area. Over the last two years, the company has fully refurbished all three clinics. The clinics deal with up to 200 patients a day, some who walk 20 km for treatment.

www.astrazeneca.com

Aventis

Through the WHO-Aventis Sleeping Sickness Partnership, Aventis committed $25 million to accelerate disease control and prevention and research and development activities. Further, Aventis donated three drugs to the WHO to treat the disease.

Global Alliance for Vaccines and Immunizations

With the help of its partners, Aventis, The Bill and Melinda Gates Foundation, the WHO, developing country governments, international organizations and NGOs, GAVI works to improve access to, expand use of, and make immunization efforts a centerpiece of public health policy.

As part of its contribution to GAVI, Aventis is financing the training of 250 medical experts who will organize immunization campaigns in several African countries.

In the past three years, Aventis has donated more than 2 million doses of vaccines to Cuba, Ecuador, North Korea and the Philippines.

AIDS Vaccine Research

Aventis continues its R&D efforts toward the creation of an AIDS vaccine. In July 2003, Thailand announced the world’s largest HIV vaccine trial using an HIV vaccine developed by Aventis Pasteur and VaxGen.

Global Polio Eradication Initiative

Through this initiative, Aventis has donated over 130 million polio vaccines to African countries affected by conflict. A total of 530 million children were immunized against polio in 2000, 152 million of them in India. In addition to product donation, Aventis works closely with the WHO, Rotary International, CDC and UNICEF to create educational programs for health workers.

TB Free Project in South Africa

Since May 2002, Aventis has worked in partnership with the Nelson Mandela Foundation to increase testing, care and treatment of TB in South Africa.

Aventis’ global healthcare activities involve the company in preventing and treating a wide range of diseases. For example, Aventis Tropical Disease Center in Brazil works to control malaria and encourage early diagnosis and treatment of leishmaniasis throughout the country.

Project OPTIMAL based in Cote d’Ivoire identifies new ways to use existing therapies to reduced mortality and morbidity of malaria.

In November 2003, Aventis helped conduct a diabetes training program in Togo. In March 2004, Aventis donated genetically engineered human insulin valued at
$70,000 to the Health Ministry of the Kyrgyz Republic for patients of diabetes mellitus.

In Myanmar, Aventis sponsors a model project for healthcare in schools, while in Bhutan, Aventis supports a program to prevent parasitic infections.

www.aventis.com

Bayer Corporation Pharmaceutical Division

Bayer and the Medicines for Malaria Venture (MMV), a foundation financed by the World Bank and private organizations and initiated by the WHO, have agreed to cooperate on the development of a new malaria drug. Under this agreement, Bayer will be in charge of product development, while the WHO “Roll Back Malaria” program will be responsible for controlled distribution in the public health systems of the developing countries. Bayer will provide the product for the program. The price in this market segment is to be set at a level that will enable all sections of the population in the developing countries to afford malaria treatment.

Bayer also participates in programs to promote malaria prevention in Malawi, Mali, Zambia, Turkey and Uganda.

In partnership with the WHO, Bayer will donate Germanin at no cost for five years to combat sleeping sickness in developing countries. In addition to the product donation, Bayer is conducting R&D on the off-label use of its Chagas Disease product to treat Sleeping Sickness.

Bayer is supporting programs to combat dengue fever in Brazil, Dominican Republic, El Salvador, Guatemala, Ecuador and Paraguay.

In 2000, Bayer provided support to the Children in Need Foundation for the construction of a diagnostic and research laboratory in Singureni, Romania. Its focus is on the testing of orphans, street children and young adults who may be HIV positive.

Bayer’s La Milagrosa project provides basic healthcare services and medicines to residents in rural Bolivia.

Since 1997, Bayer has donated more than €2 million in antibiotic, antihypertensive, antifungal and antirheumatic drugs to Bulgaria’s state-run hospital system.

Bayer Taiwan and the Hemophilia Association of Taiwan host the Overseas Summer Hemophilic Camp for young patients, their parents and their caretakers.

www.bayer.com

Boehringer Ingelheim Pharmaceuticals, Inc. ~

Boehringer Ingelheim, Abbott Laboratories, Axios International, Elisabeth Glaser Pediatric Foundation, Catholic Medical Mission Board and Family Health International have formed a cooperative agreement to help prevent mother-to-child transmission of HIV in the developing world. The program focuses on testing and treatment using Abbott’s rapid HIV test and VIRAMUNE®, an ARV made by BI.

VIRAMUNE® has been donated to 100 programs in 50 countries, including China, Russia and Peru.

BI, International Council of Nurses, Zambian Nurses Association and the Government of Zambia provide VIRAMUNE® to pregnant nurses to prevent mother-to-child transmission of HIV.

Christopher Hentschel
MMV Chairman

“Medicines for Malaria Venture was created out of the conviction that public/private partnerships can be the right way to successfully combat such scourges of humanity as malaria.”

Photo: Courtesy of Bristol-Myers Squibb

9
BI granted a license to a South African generic firm to manufacture and market a generic version of VIRAMUNE® in Africa. www.boehringer-ingelheim.com

**Bristol-Myers Squibb Company** – In 2003 donations of medicines supported humanitarian aid partners working around the world and totaled some $36 million in wholesale value.

**SECURE THE FUTURE®**

Since its creation in 1999, **SECURE THE FUTURE** has addressed the needs of women and children affected by HIV/AIDS. The program has provided grants totaling almost $100 million to more than 160 community and medical research programs in nine countries in southern and western Africa.

In the past two years, the program has funded two care centers for children with HIV in Africa.

In November 2003, BMS announced six community-based grants totaling $30 million. The grants will fund education, prevention and treatment programs aimed at women and children affected by HIV/AIDS. The grants will be implemented in Swaziland, Namibia, Lesotho, Botswana and South Africa.

Using a grant from **SECURE THE FUTURE**, researchers have developed a low-cost CD4 test to monitor immune system function and progression of patients with HIV/AIDS. The low-cost CD4 test has been licensed to the South African National Health Laboratory Service. Researchers estimate that the new CD4 test could result in cost savings of 70 to 80 percent in comparison to traditional testing methods.

In January 2003, **SECURE THE FUTURE** published **HIV Curriculum for Health Care Professionals**. The publication is designed to provide healthcare workers with the most relevant information concerning HIV/AIDS prevention, diagnosis, care, treatment options and social and ethical issues.

**Other Global Health Programs**

BMS and the Thai Red Cross AIDS Research Center provide information about HIV prevention to young people between the ages of 15 to 24 years.

In partnership with International Medical Corps, BMS is seeking to develop a pilot 16-month community-based mental health program for women in Kabul, Afghanistan.

BMS and the China Foundation for Hepatitis Prevention and Control educate local healthcare workers, physicians and villages on hepatitis prevention, care and treatment.

BMS provides product donations to Direct Relief International’s Rio Beni Health Project in the upper Amazon region of northwestern Bolivia. The project provides primary healthcare, education and training.

BMS is working with Project HOPE in Nicaragua to improve the health of mothers and children in an impoverished coffee-growing region with product donations that address basic health needs. Other programs are underway in the Dominican Republic, Mexico, and the newly independent states of the former Soviet Union.

BMS supports International Aid’s Medical Equipment Training Program, which links medical technicians in developing countries with the knowledge and supplies needed to maintain equipment. The program operates in Kosovo, Honduras, Ghana and the Philippines.

“SECURE THE FUTURE is establishing a new paradigm for combating the AIDS pandemic in Africa. The unique approach of offering both community and medical services is critically important to efforts to stem the devastation of this disease.”

*Dr. Pearl Ntsekhe*  
Lesotho Ministry of Health and Social Welfare

“The relationships we forged through **SECURE THE FUTURE** are as important as the funds we received. Our partners helped us with process and procedure improvements, they showed us how to achieve our objectives better and they enhanced the well-being of our entire organization.”

*Reverend Edward Baralemwa*  
Pan African Christian AIDS Network

Product donations also supported disaster relief efforts in Iran, Iraq, Liberia, Somalia and the Congo in conjunction with such partners as Direct Relief International, Catholic Medical Mission Board, Interchurch Medical Assistance, and MAP International. www.bms.com
Eli Lilly and Company — Over the past several years, the company and the Lilly Foundation have provided more than $100 million in product donations and cash grants to developing countries.

Launched in July 2003, Lilly’s MDR-TB (Multi-Drug Resistant Tuberculosis) program is a $70 million partnership with the WHO, U.S. Centers for Disease Control and Prevention, Brigham and Women’s Hospital, Purdue University and the International Council of Nurses. The MDR-TB program combines prevention, care, surveillance and treatment. Additionally, Lilly has signed technology transfer agreements in India and South Africa to increase manufacturing know-how. Additionally, Lilly provides financial assistance for the purchase of equipment and/or conversion of manufacturing facilities and technical training for the various phases of manufacturing.

In November 2003, Lilly announced a partnership agreement with Brigham and Women’s Hospital and the International Council of Nurses to create a research and training program on MDR-TB in Siberia. The program will conduct operational and epidemiological research to support MDR-TB control programs. Additionally, the program includes ongoing training of local healthcare workers.

Tuberculosis Initiative

In 1999, Lilly established a philanthropic program to improve access to TB care worldwide. Working with the WHO and Médecins Sans Frontières (MSF), Lilly now distributes a significant amount of its production of capreomycin and cycloserine via the WHO’s DOTS Plus (Directly Observed Treatment Short Course) program at a fraction of production cost. Through the WHO Green Light Committee, Lilly has been an active participant in the treatment of thousands of MDR-TB in patients globally, including in Peru, Russia and the Philippines.

In South Africa, Lilly provides funding for individuals to attend local pharmacy and medical schools. Lilly has provided a grant to the Centre for Diabetes Education to develop an outreach program and infrastructure to offer diabetes education and treatment to patients with diabetes in the townships and suburban areas of Johannesburg, Cape Town and Durban. At the end of 2002, the Lilly Diabetes Clinic opened in an impoverished area of Johannesburg.

Lilly supports Project HOPE’s Diabetes Initiative, which runs two extensive diabetes management programs, one in China and one in Egypt. Lilly has also made a three-year, $180,000 commitment to the International Diabetes Foundation Child Sponsorship Foundation to help children and adolescents in developing countries acquire the medicines, equipment and knowledge needed to manage diabetes.

As part of Lilly’s support of the WHO, the company provided more than $5 million to the Nations for Mental Health Project. This multifaceted project to improve mental health in developing countries is a collaboration of the WHO, NGOs, and the private sector.

Lilly is funding a United Nations High Commission for Refugees educational program in 2004 for 60 Afghan refugee women to take courses such as physiotherapy and clinical pathology.

www.lilly.com
**Genzyme Corporation** – Genzyme works in partnership with Project HOPE to provide enzyme therapy to 150 patients in Belarus, China, Cuba, Ecuador, Egypt, Haiti, India, Jamaica, Kenya, Pakistan, Sri Lanka, Tanzania, Ukraine, Vietnam and Yugoslavia. www.genzyme.com

**GlaxoSmithKline** – GSK’s African Malaria Partnership is providing $1.5 million in seed funding over three years to support malaria education programs for 2 million people in seven African nations.

In 2003, GSK launched Lapdap, an anti-malarial treatment developed in partnership with GSK researchers, scientists in Africa, two leading UK medical schools, the WHO and the UK Government. GSK is registering Lapdap across sub-Saharan Africa, where it will be available to national malaria control programs at preferential prices.

In April 2004, GSK and the WHO Special Programme for Research and Training in Tropical Diseases entered into a cooperative agreement to develop a fixed-dose combination therapy drug for treatment of malaria.

In February 2003, GSK launched its new meningitis vaccine, developed in partnership with the WHO. The vaccine is available to 21 African countries at a preferential price of €1 per dose.

In October 2003, GSK signed a technology transfer, supply and license agreement with the Brazilian government for the production of the measles, mumps and rubella vaccine. This partnership enables more than 100 million children in Brazil to be vaccinated over the next five years.

The Integrated Management of Childhood Illness aims to reduce deaths from treatable and preventable diseases by improving the skills of health workers and helping families better care for sick children. GSK has provided funding of $300,000 and technical expertise. In 2003 the initiative was expanded from South Africa and Ethiopia into Namibia and Nigeria.

In China, GSK is working in partnership with the British and Australian Red Cross to reach young people and drug users to prevent the spread of HIV. During 2003, 8,000 young people took part in training and the program has reached 14,000 people since its creation.

In 2003, GSK donated medicines worth £105 million to patients in over 80 countries including Iraq, India, Nicaragua, and Iran (following the devastating Bam earthquake.)

GSK donated 94 million albendazole tablets, valued at £111 million, to the WHO’s Global Program to Eliminate Lymphatic Filariasis (LF). In total, GSK has donated over 250 million tablets to assist the efforts of almost 40 countries. By 2020, officials at GSK predict that donations will total £1 billion in value.

In 2003, GSK extended the voluntary license granted to the generics manufacturer Aspen Pharmacare to include sales to the private market. Under this agreement, Aspen Pharmacare can

In 2003, GSK donated $25,000 to Plan International to assist with relief operations and an increase in malaria cases in Sudan following severe flooding.

GSK’s ARVs and anti-malarial medicines are available to the public sector at not-for-profit prices in 63 of the world’s poorest countries, including all of sub-Saharan Africa. In December 2002, the not-for-profit price for the ARV Combivir was reduced by 62 percent to $0.65 per day.

In 2003, GSK provided a two-year grant valued at £1.0 million for two HIV/AIDS clinics in Malawi and Uganda and over £500,000 in grants for HIV programs in Africa.

The GSK France Foundation supports a range of programs to improve access to healthcare for HIV-positive people in Africa, particularly women and children. Over the last five years, the foundation has provided £2 million to support 32 programs in 13 African countries.
manufacture and sell key GSK ARVs across sub-Saharan Africa, in both the public and private sectors. Discussions are underway with a second generics manufacturer on a similar license for GSK ARVs across Africa.

GSK is supporting 27 clinical trials in developing countries to assess the use of ARVs in resource-poor settings. Seven new studies began in sub-Saharan Africa in 2003, bringing the total in this region to 20. This includes the DART study, the largest HIV treatment study in Africa involving 3,000 patients in Uganda and Zimbabwe. Additionally, GSK supplies drugs for eight studies of prevention of mother-to-child HIV transmission, involving 8,000 patients in developing countries.

Hoffmann-La Roche Inc.

Since the creation of this initiative in 1986, Roche, the WHO and UNICEF have sponsored over 1,500 programs in 80 countries to address Vitamin A deficiency in the developing world. Severe Vitamin A deficiency is fatal and often leads to blindness in young children.

In September 2003, Roche, Government of Cambodia and University of New South Wales, Australia launched the Cambodia Treatment Access Project. Its aim is to increase access to HIV care, conduct research and train healthcare workers in Cambodia, estimated to have the highest rate of HIV infection among adults in Asia.

On April 1, 2004, Roche announced the following policies for its patented products:

- Roche will not file patents on new ARV therapies in the LDCs and sub-Saharan Africa.
- Roche will not take action against generic versions of its ARV therapies where Roche holds, or has license in, the patent in the LDCs and sub-Saharan Africa.
- Roche holds no patents for its malaria treatments—Fansidar or Lariam—in the LDCs or sub-Saharan Africa.

Roche has developed a pricing policy for its HIV protease inhibitors to help increase access to these medicines. Roche’s two HIV protease inhibitors, Viracept® (nelfinavir) and Invirase® (saquinavir), are defined by the WHO as essential medicines, and are made available at no profit to the LDCs and sub-Saharan Africa.

www.rocheusa.com

Johnson & Johnson

Johnson & Johnson has partnered with a number of governmental, international and NGOs in an effort to combat the spread of HIV/AIDS around the world. For example, J&J and the Elizabeth Glaser Pediatric AIDS Foundation support the Call to Action Program to help prevent mother-to-child transmission of HIV in resource-poor nations such as India. The program expects to reach 4,000 women with counseling and testing services in its first year and 8,000 women in its second year. Women who are HIV positive will be offered ARV therapy to prevent transmission of the virus to their babies. In Burkina Faso, Kenya, Malawi, Mozambique, Burundi and Tanzania, J&J works in partnership with other organizations to provide a once-a-day treatment for oropharyngeal candidiasis, a common opportunistic infection in the mouth and throat in people with HIV/AIDS. The treatment can have a dramatic impact on quality of life of patients by rapidly restoring their ability to eat.

J&J works with HIV South Africa (HIVSA) to train and monitor home-based care organizations that offer social support to HIV and AIDS patients and their families. HIVSA and its supported organizations supplement traditional social arrangements by providing home-based care to people unable to receive medical or social support from hospitals or care centers. J&J also supports The Total Control of the Epidemic (TCE) Program in Bram Fischerville, Soweto. The program recruits, trains, and monitors TCE Field Officers who are responsible for going door-to-door and educating people about HIV and AIDS.

In India, J&J works with the Peoples Health Organization of India to sponsor a mobile van that provides family and crisis counseling for those affected by HIV and AIDS, distributes free condoms, and leads people living with HIV or AIDS to HIV-friendly hospitals or NGOs by acting as a referral
J&J provided Vitamin Angel Alliance with a one-year grant to fund the administration of high-dose vitamin A supplements to 250,000 children in India. Vitamin Angel Alliance is a nonprofit organization that launched an international initiative aimed at eradicating vitamin A deficiency-related blindness in children by 2020.

www.j&j.com

**Merck & Co., Inc.** ~ Merck’s global health programs help people in developing countries around the world. In 2003, the company donated $69 million in pharmaceuticals and vaccines in five continents. The value of its medicine donations throughout the developing world totaled $396 million in 2003 alone.

Since 2000, the African Comprehensive HIV/AIDS Partnerships in Botswana program, sponsored in partnership by Merck & Co., Inc., the Government of Botswana, and The Bill and Melinda Gates Foundation has supported and enhanced Botswana’s national response to the HIV epidemic. Projects include:

- Improving the effectiveness and availability of voluntary testing, referral and diagnostic services;
- A condom distribution and marketing program, including the installation of more than 10,000 condom dispensers providing free condoms throughout the country;
- Providing small grants to fund community-based initiatives;
- Building resource centers at hospitals and daycare facilities for orphans;
- Establishing support and counseling services including faith-based services, pre- and post-test counseling and interventions targeting youth and other vulnerable groups;
- Implementing awareness, knowledge and de-stigmatization campaigns through the national education and broadcast systems; and
- Healthcare worker training encompassing both theoretical and practical training.

Since 1997, the Romanian government and Merck have worked together to increase access to treatment for thousands of children and adults living with HIV/AIDS in Romania, home to nearly 60 percent of Europe’s pediatric AIDS cases.

In March 2004, J&J, through its Tibotec Pharmaceuticals Limited subsidiary, entered into an agreement with the International Partnership for Microbicides to provide the promising new drug TMC120 to prevent sexual transmission of HIV in resource-poor countries.

In 2003 J&J provided medical supplies to victims of the earthquake in Bam, Iran, and more than $40,000 toward relief efforts in the Xinjiang region of China after an earthquake.

In response to the urgent medical needs of the 18 million people in Afghanistan, J&J committed $10 million in medical product contributions to Direct Relief directly from its Karachi, Pakistan, manufacturing plant in June 2002, the largest commitment of medical resources to a single country in Direct Relief’s 55-year history. The resources are being provided to two “Mother and Child” Health Clinics in Kabul and Peshawar, Pakistan, as well as the Afghan Institute for Learning, which operates Maternal & Child Health Clinics in Jalalabad and Kabul.

and guidance center. In Cambodia, J&J supports a peer training program for HIV-infected youth.
The Merck Mectizan™ Donation Program

Through this program, Merck has provided more than 850 million tablets of Mectizan (ivermectin) free of charge to people at risk for onchocerciasis (river blindness) in some of the poorest countries in the world. Since the program began in 1987, it has grown to reach more than 30 million people annually in more than 30 countries where river blindness is endemic. The program has become an unparalleled worldwide endeavor that includes the WHO, World Bank, UNICEF, numerous NGOs, ministries of health, and over 60,000 infected communities.

On April 5, 2004, Merck signed a letter of intent to grant a non-exclusive patent license for the manufacture and sale of a generic version of Efavirenz to Thembalami Pharmaceuticals (Pty) Ltd., the joint venture partner of Adcock-Ingram, for South Africa and other countries in the Southern African Development Community. Efavirenz is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection, sold by MSD under the trade name STOCRIN. The license will cover both the public and private sectors in these countries.

In November 2003, Merck announced the Merck Vaccine Network - Africa (MVN-A), an initiative designed to contribute to improving the immunization infrastructure in Africa. The multi-year program will fund the establishment of a network of vaccination training centers at academic institutions in Kenya and Mali to provide a sustainable source of skilled healthcare workers in those countries and across the region.

Since March 2001, Merck has sold its HIV medicines STOCRIN and Cravisivan in the LDCs at no profit on these products and provided significant discounts to other poor countries. As of April 2003, 73 countries have accepted Merck’s offer of reduced prices and ARVs have already been shipped to patients in 57 of these countries.

www.merck.com

Novartis – Novartis works with the WHO and others to deliver effective treatments for malaria to patients in developing countries. In 2003, Novartis donated $4 million worth of its anti-malaria drug and reached 460,000 patients in Africa, Asia and Latin America. In 2004, Novartis expects to provide 10 million treatments.

Novartis and the Medicines for Malaria Venture are working together to develop a version of the medicine for children.

Novartis has worked with the WHO since 2000 to provide free leprosy drugs to developing countries. Novartis will provide free leprosy drugs until 2005. In 2003, Novartis’ donation was valued at $4 million and reached 600,000 patients worldwide. Additionally, Novartis will maintain a buffer...
2003, Novartis’ donation was valued at $1 million and reached 34,500 patients worldwide.

The Novartis Institute for Tropical Diseases in Singapore works to discover new treatments and prevention methods for tropical diseases and make them available at no profit. Research focus of the institute includes TB and dengue fever. The mission of the institute is to create a graduate and post-graduate training program open to scientists from developing countries. Presently the institute is host to 70 permanent scientists and 30 students. Two drug discovery projects have already progressed to the stage of lead optimization/chemical fine-tuning of candidate compounds. To date, Novartis has provided $122 million toward this program.

Pfizer

Diflucan® Partnership Program

Pfizer donates Diflucan® (fluconazole) through governmental organizations in the world’s LDCs most in need. While Diflucan is not an HIV/AIDS treatment, it is effective in treating two serious fungal opportunistic infections associated with the disease, cryptococcal meningitis and esophageal candidiasis. In addition to providing free medicine, Pfizer partners with the International Association of Physicians in AIDS Care (IAPAC) to train healthcare professionals in the diagnosis and treatment of fungal opportunistic infections. Program donations have been made to governments and NGOs in countries hardest hit by HIV/AIDS: Botswana, Cambodia, Cameroon, Gambia, Ghana, Haiti, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, Senegal, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zanzibar and Zimbabwe.

"Trachoma control is a struggle against disease, a struggle against blindness and a struggle against illiteracy, and that depends on the behavioral change of a population. Other companies should learn from Pfizer to work with governments and others, because success can only happen with the involvement of all these actors working together."

Dr. Youssef Chami-Khazraji
Moroccan Ministry of Health

stock for fluctuations/outbreaks of leprosy and fund shipment and quality control efforts.

Sponsored by the Novartis Foundation and Terres des Hommes Switzerland, Humuliza has provided psychological care for AIDS orphans in the region of Kagera, Tanzania, since 2001.

In 2003, Novartis emergency relief efforts were valued at $19 million and reached 325,000 people worldwide.

Novartis worked with local NGOs to donate intraocular lenses for cataract surgery for patients with inadequate financial means. In
In April 2004, Pfizer and the Ethiopian Health Ministry announced a new partnership agreement to provide Diflucan free to AIDS patients. Pfizer will provide more than 50,000 Diflucan tablets. The government will distribute the free pills to 16 public hospitals providing treatment to AIDS patients.

International Health Literacy Grant Program

The Pfizer Foundation supports innovative HIV/AIDS health promotion programs that target health providers, patients, caregivers and those at high-risk of HIV infection living in countries where Pfizer is donating Diflucan. Projects use creative approaches to convey key messages regarding HIV/AIDS prevention, care and treatment.

Pfizer Global Health Fellows Program

Announced in July 2003, Pfizer’s Global Health Fellows Program will loan Pfizer physicians, nurses, epidemiologists, laboratory technicians, health educators and IT specialists from the United States, Europe, Latin America, Australia and Africa to NGOs working to fight HIV/AIDS and other diseases in developing countries. To date 31 fellows have been deployed in the field, with another 15 expected by the end of 2004.

International Trachoma Initiative

Pfizer partnered with the Edna McConnell Clark Foundation in 1998 to found the International Trachoma Initiative (ITI). Through this initiative, Pfizer provides its key antibiotic, Zithromax, to countries implementing public health programs to combat trachoma, the world’s leading cause of preventable blindness. The program includes community-based initiatives to provide surgery, antibiotics, promotion of clean faces and education about the disease.

Infectious Diseases Institute

In partnership with the Academic Alliance for AIDS Care and Prevention and the San Francisco AIDS Foundation, Pfizer supported the construction of a medical training facility, the Infectious Diseases Institute, in Kampala, Uganda. This recently opened facility provides state-of-the-art HIV/AIDS care to thousands of patients each year and trains hundreds of Ugandan physicians and those in the region in the latest HIV/AIDS standards of care.

Global Community Matching Fund

The Pfizer Foundation’s Global Community Matching Fund supports local charitable projects throughout the world to benefit the communities where Pfizer people live and work. These projects are primarily health-related. For example, the fund is working with Vision Mundial to construct 20 medical clinics in Mexico and six throughout Central America.

www.pfizer.com
Sanofi-Synthelabo Inc. — Sanofi works with governments, major international institutions, universities and research institutes to control malaria in developing countries by providing education, prevention and treatment information to healthcare providers and patients. Impact Malaria works with developing countries to provide treatment at affordable prices.

Sanofi also sponsors hepatitis B vaccinations in Vietnam and Colombia and programs promoting dental care and eyecare in Turkey, Hungary and China.

Sanofi supports the Fun Center project in Brazilian, American and British hospitals. Fun Centers provide children with an opportunity to “escape” their illness and open a window to life and hope.

www.sanofi-synthelabous.com

Schering-Plough — In 2002, SP provided over $9.0 million in grants and matching gifts to support nonprofit organizations and academic institutions.

www.sch-plough.com

The Proctor & Gamble Company — Over the past several years, P&G and UNICEF have worked together in more than two dozen countries on five continents. Programs have ranged from providing TB vaccinations to more than 8 million people in Senegal, supporting education programs for 190,000 children in Vietnam, and providing water and sanitation facilities to more than 32,000 people in the Philippines.
P&G’s Beijing Technical Center is partnering with Langfang Children’s Village, which care for some of China’s most needy citizens. The Langfang Children’s Village takes in “at risk” orphans, provides medical and surgical treatment, and cares for them in a family atmosphere until they can be adopted.

P&G Egypt is working with the Egyptian Ministry of Health to prevent the spread of waterborne diseases such as schistosomiasis and fasciola. The partnership has been running a test of “washing stations” in the Nile Delta village of Tiba. Each washing station, which pipes in clean water, consists of 20 sinks, a washroom, clotheslines, and wastewater treatment unit.

In 2003, the P&G Fund donated over $84 million in products worldwide.

www.p&g.com

Wyeth is a member of the Partnership for Quality Medical Donations (PQMD). The PQMD is a non-profit alliance of major NGOs and 10 pharmaceutical and medical companies. Its mission is to improve the process for procuring and distributing donated products to better meet the needs of underserved populations and disaster victims around the world. Project HOPE, AmeriCares and Health to Heart International are recipients of significant donations of Wyeth products in recent years.

www.wyeth.com

“What I can say with a lot of certainty is that regarding private-public partnership, synergy is really crucial. We heard the Franciscan sister speaking, we heard the pharmaceutical industry speaking, and we heard governments speaking. There is nobody who can afford to stay away.”

Ms. Christine Kapalata
Permanent Mission of the United Republic of Tanzania to the UN
2000  Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Roche, together with UNAIDS, the WHO, UNICEF, UNFPA and World Bank, establish the Accelerating Access Initiative to increase access to HIV/AIDS care and treatment in developing nations. Abbott Laboratories joined the initiative subsequently.

The Merck Company Foundation and the Bill & Melinda Gates Foundation pledge $50 million each over five years to the African Comprehensive HIV/AIDS Partnerships in Botswana, a joint initiative of the Government of Botswana, Gates Foundation and Merck. Merck also agrees to donate its ARVs free of charge to Botswana’s treatment programs for the duration of the program.

Boehringer Ingelheim offers to supply VIRAMUNE® free to developing nations for five years to prevent mother-to-child transmission of HIV.

Pfizer establishes the Diflucan Partnership Program with the South African Ministry of Health and donates free doses of the anti-fungal drug Diflucan® to treat cryptococcal meningitis and oesophageal candidiasis, life-threatening opportunistic infections associated with HIV/AIDS.

2001  Abbott begins work on Tanzania Care, a partnership with the government of Tanzania to build the country’s AIDS response/management system, including a national AIDS program, AIDS care guidelines, HIV testing system and training for medical professionals.

GlaxoSmithKline extends its 90 percent discount on HIV/AIDS medicines to NGOs in developing countries and employers in Africa who offer care to their workers.

Roche and PharmAccess International announce a new initiative to create access to anti-HIV drugs in four African countries, beginning with major urban treatment centers in Cote d’Ivoire, Kenya, Senegal and Uganda. Roche provides funding, ARV agents, diagnostic and monitoring tests, and technical support for training of healthcare professionals and patient education.

Merck & Co., Inc. offers its ARVs—Crixivan and STOCRIN—at no-profit prices in the LDCs and those nations hardest hit by the epidemic, and at significant discounts in other countries in the medium category of the Human Development Index—more than 110 countries in all.

Bristol-Myers Squibb makes the patent for Zerit [d4T] available at no cost to treat AIDS in South Africa and offers to sell ddI and Zerit below cost.

2002  Roche and PharmAccess International begin patient enrollment in the CARE partnership pilot program to deliver comprehensive HIV care in four African centers. A year later, with support and funding from Roche, the program is providing access to HIV care for patients throughout Africa.

Abbott pledges to donate up to 20 million Determine HIV-1/2 rapid tests over five years to programs for the prevention of mother-to-child transmission of HIV in Africa and the 49 LDCs. Abbott also announces further reductions in the Abbott Access prices for its ARVs Norvir and Kaletra, offering to sell them at a loss to the company.

Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Roche sign statements of intent with the Economic Community of Western African States and the Caribbean Community to expand access to HIV/AIDS care and treatment through the Accelerating Access Initiative.

Roche makes Invirase and Viracept pediatric powder available at no-profit prices to the LDCs and in sub-Saharan Africa.

GlaxoSmithKline further reduces the no-profit preferential prices of its HIV/AIDS medicines by up to 33 percent and its anti-malarial medicines by up to 38 percent. GSK will also supply these medicines at no-profit prices to all projects fully financed by the Global Fund to Fight AIDS, TB and Malaria.

Merck & Co., Inc. offers to make the new 600-mg. tablet formulation of STOCRIN available at less than one dollar per day in the LDCs and those hardest hit by the HIV/AIDS epidemic.
Pfizer and The Pfizer Foundation announce that the Diflucan Partnership Program will be extended indefinitely.

2003 Ministers of health of Panama, Costa Rica, El Salvador, Guatemala, Honduras and Nicaragua reach individual agreements in the framework of the Accelerating Access Initiative with Boehringer Ingelheim, Bristol-Myers Squibb, Roche, GlaxoSmithKline and Merck & Co., Inc. to implement or maintain pricing policies that will lead to significant discounts (up to 85 percent, and 55 percent on average) for ARV treatments in Central America and to a substantial increase in the number of people in the region with access to HIV/AIDS care and treatment.

Boehringer Ingelheim announces the extension of its VIRAMUNE® donation program beyond its original 5-year period. The program operates 100 initiatives in 48 countries.

Bristol-Myers Squibb announces a grant of $115 million for a second care center for children with HIV in Africa.

2004 The Accelerating Access Initiative announces that the number HIV patients in Africa receiving ARV treatment provided by member companies doubled to more than 150,000 in the last six months of 2003.

Johnson & Johnson enters into an agreement with the International Partnership for Microbicides to provide a new drug to prevent sexual transmission of HIV in resource-poor countries.

Roche announces that the company will not file or enforce any patents on medicines in the LDCs and will not take action against generic versions of its ARVs in these countries.

Pfizer and the Ethiopian Health Ministry announce a new partnership agreement to provide Diflucan free to AIDS patients. By November 2004, Pfizer’s Diflucan Partnership Program is operating in 23 countries in Africa, Asia, Caribbean and Latin America.

Roche announces no-profit prices for direct sales of Viracept and Invirase to LDCs and in sub-Saharan Africa.

Merck & Co., Inc. signs a letter of intent to grant a non-exclusive license for the manufacture and sale of a generic version of Elavirenz to Thembalami Pharmaceuticals in South Africa.

Merck, Bristol-Myers Squibb and Gilead announce the first ever multi-company effort to develop a once-a-day, fixed dose combination of three anti-HIV drugs.

As of November 2004, 80 countries have indicated their interest in participating in the Accelerating Access Initiative. In 49 of these 80 countries, national plans to improve access have been or are being developed. These same 49 countries, including countries in sub-Saharan Africa, Chile, Honduras, Jamaica, Morocco and Ukraine, have reached agreements with manufacturers on significantly reduced drug prices.